Novel immunotherapeutic drugs for the treatment of lung cancer

Peng, Ling; Wang, Zibing; Stebbing, Justin; Yu, Zhentao

doi:10.1097/cco.0000000000000800

Cited by 14 publications

(11 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report antibodies, with most attention on tumor immunotherapy (8,9), represented by programmed cell death protein-1 (PD-1) inhibitors. Pembrolizumab, a PD-1 inhibitor that has shown promising results in tumor-related clinical trials, has been approved for new tumor indication and is recommended in antitumor guidelines in several countries (10)(11)(12).…”

Section: Case Reportmentioning

confidence: 99%

“…With the emergence of new drugs and optimization of treatment modalities, the prognosis of lung cancer patients has improved to some extent ( 6 , 7 ). In recent years, attention has focused on the many approved antitumor new drugs, in addition to various small molecule tyrosine kinase inhibitors and macromolecular monoclonal antibodies, with most attention on tumor immunotherapy ( 8 , 9 ), represented by programmed cell death protein-1 (PD-1) inhibitors. Pembrolizumab, a PD-1 inhibitor that has shown promising results in tumor-related clinical trials, has been approved for new tumor indication and is recommended in antitumor guidelines in several countries ( 10 - 12 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report

Zhang¹,

Huang²,

Chen³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Lung cancer is a malignant tumor with high morbidity and mortality, and its incidence continues to increase. With the emergence of new drugs and treatment modalities, the prognosis of lung cancer patients has improved to some extent. However, the prognosis of initially unresectable, locally advanced lung cancer with immunotherapy combined with chemotherapy remains uncertain.Case Description: We report a case of a 57-year-old man diagnosed with stage IIIB la with negative targeted therapy-related gene mutation and a 2% programmed death 1/programmed cell death-ligand 1 (PD-1/PD-L1) expression level, who underwent transformation treatment with pembrolizumab after multidisciplinary consultation. Lung images indicated partial response after 4 cycles. However, preoperative examination found hypothyroidism considered the immune-related, and giving hormone replacement treatment after the endocrinology department consultation. Thyroid function improved after 1 month.The patient successfully underwent single-hole thoracoscopic radical lung cancer (left whole lung resection + mediastinal lymph node dissection). Postoperative pathology was consistent with major pathological remission (MPR). The patient was scheduled to receive 8 cycles of single-drug maintenance therapy with pembrolizumab after surgery. To date, no tumor recurrence and metastasis have been found at follow up, and maintenance treatment continues to improve.Conclusions: This case reminds us that the induction treatment pattern of pembrolizumab combined with chemotherapy for subsequent conversion surgery can be a potentially curative treatment option for locally advanced stage IIIB patients. The monitoring of thyroid-related indicators is important during immunotherapy, especially in the first 1-2 months. The cause of thyroid dysfunction should be detected early so that it can be treated promptly to improve the prognosis of the patient. Pembrolizumab in combination with paclitaxel and platinum drugs provides a new option for patients with locally advanced stage IIIB lung squamous cell carcinoma who eager to undergo radical surgery.

show abstract

Section: Case Reportmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report

Zhang¹,

Huang²,

Chen³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…The anti-PD-L1 monoclonal antibodies have durvalumab and atezolizumab in NSCLC. Anti-CTLA-4 (ipilimumab) is also be used in lung cancer because of CTLA-4 as a checkpoint on lymphocytes ( Ackermann et al, 2019 ; Dawe et al, 2020 ; Peng et al, 2022 ). However, PD-1/PD-L1 monoclonal antibodies and anti-CTLA-3 treatment obtain a good response in a subgroup of lung cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Wang

Zhu²,

Yang³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.

show abstract

“…Among the lung cancer histological subtypes, non-small cell lung carcinoma (NSCLC) is the most frequent histological subtype, representing at least 85% of all cases [ 5 ]. The therapeutic strategy of advanced-stage or metastatic NSCLC, notably of non-squamous (NS)-NSCLC, has evolved dramatically in the last few years, thanks to the development of new targeted therapies and immune checkpoint inhibitors (ICIs) administered alone or in association with chemotherapy and targeted therapies [ 6 , 7 , 8 ]. These different therapies have significantly increased the overall survival of NS-NSCLC patients [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner

Bontoux

Hofman

Brest

et al. 2022

Cancers

View full text Add to dashboard Cite

KRAS mutations are among the most frequent genomic alterations identified in non-squamous non-small cell lung carcinomas (NS-NSCLC), notably in lung adenocarcinomas. In most cases, these mutations are mutually exclusive, with different genomic alterations currently known to be sensitive to therapies targeting EGFR, ALK, BRAF, ROS1, and NTRK. Recently, several promising clinical trials targeting KRAS mutations, particularly for KRAS G12C-mutated NSCLC, have established new hope for better treatment of patients. In parallel, other studies have shown that NSCLC harboring co-mutations in KRAS and STK11 or KEAP1 have demonstrated primary resistance to immune checkpoint inhibitors. Thus, the assessment of the KRAS status in advanced-stage NS-NSCLC has become essential to setting up an optimal therapeutic strategy in these patients. This stimulated the development of new algorithms for the management of NSCLC samples in pathology laboratories and conditioned reorganization of optimal health care of lung cancer patients by the thoracic pathologists. This review addresses the recent data concerning the detection of KRAS mutations in NSCLC and focuses on the new challenges facing pathologists in daily practice for KRAS status assessment.

show abstract

Novel immunotherapeutic drugs for the treatment of lung cancer

Cited by 14 publications

References 49 publications

Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report

Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner

Contact Info

Product

Resources

About